bumetanide has been researched along with Suffocation in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent experimental data suggest bumetanide as a possible therapeutic option in newborn infants with seizures after birth asphyxia." | 9.22 | Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ( Blennow, M; Boylan, G; Chiron, C; Jullien, V; Marlow, N; Pons, G; Pressler, RM, 2016) |
| "For bumetanide, it has been suggested that inhibition of the NKCC isoform NKCC1 in the membrane of brain neurons may be involved; however, NKCC1 is expressed by virtually all cell types in the brain, which makes any specific targeting of neuronal NKCC1 by bumetanide impossible." | 5.91 | The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia. ( Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B, 2023) |
| "Recent experimental data suggest bumetanide as a possible therapeutic option in newborn infants with seizures after birth asphyxia." | 5.22 | Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures. ( Blennow, M; Boylan, G; Chiron, C; Jullien, V; Marlow, N; Pons, G; Pressler, RM, 2016) |
| "For bumetanide, it has been suggested that inhibition of the NKCC isoform NKCC1 in the membrane of brain neurons may be involved; however, NKCC1 is expressed by virtually all cell types in the brain, which makes any specific targeting of neuronal NKCC1 by bumetanide impossible." | 1.91 | The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia. ( Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Welzel, B | 2 |
| Schmidt, R | 1 |
| Kirchhoff, L | 1 |
| Gramer, M | 1 |
| Löscher, W | 2 |
| Johne, M | 1 |
| Jullien, V | 1 |
| Pressler, RM | 1 |
| Boylan, G | 1 |
| Blennow, M | 1 |
| Marlow, N | 1 |
| Chiron, C | 1 |
| Pons, G | 1 |
1 trial available for bumetanide and Suffocation
| Article | Year |
|---|---|
Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures.
Topics: Anticonvulsants; Asphyxia; Bumetanide; Female; Hearing Loss; Humans; Infant, Newborn; Male; Models, | 2016 |
2 other studies available for bumetanide and Suffocation
| Article | Year |
|---|---|
The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Topics: Animals; Asphyxia; Bumetanide; Diuretics; Epilepsy; Furosemide; Rats; Sodium Potassium Chloride Symp | 2023 |
Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia.
Topics: Animals; Anticonvulsants; Asphyxia; Asphyxia Neonatorum; Bumetanide; Epilepsy; Humans; Infant, Newbo | 2023 |